Exclusions from Patentability : How Far Has the European Patent Office Eroded Boundaries?.

By: Sterckx, SigridContributor(s): Cockbain, JulianMaterial type: TextTextSeries: Cambridge Intellectual Property and Information LawPublisher: Cambridge : Cambridge University Press, 2012Copyright date: ©2012Description: 1 online resource (374 pages)Content type: text Media type: computer Carrier type: online resourceISBN: 9781139572545Subject(s): European Patent Convention -- (1973) | European Patent Office | Patent laws and legislation -- EuropeGenre/Form: Electronic books.Additional physical formats: Print version:: Exclusions from Patentability : How Far Has the European Patent Office Eroded Boundaries?DDC classification: 346.240486 LOC classification: KJC2725 .S74 2012Online resources: Click to View
Contents:
Cover -- Exclusions from Patentability -- Title -- Copyright -- Dedication -- Contents -- Acknowledgements -- Table of cases -- EPO cases -- Enlarged Board of Appeal decisions: -- Technical Board of Appeal decisions: -- Other cases: -- Table of international conventions and regulations -- Table of official documents -- Explanation of document numbering -- Abbreviations -- 1 Introduction -- 1.1 The most basic of the safeguards -- 1.2 The 'New Wealth of Nations' -- 1.3 Natural rights as the foundation for patents? -- 1.4 Distributive justice as the foundation for patents? -- 1.5 Utilitarianism as the foundation for patents? -- 2 The historical development and current scope of the European Patent Convention -- 2.1 Introduction -- 2.2 The international harmonisation of patent law -- 2.3 The early history -- 2.4 Plant variety protection - the negotiations leading to UPOV 1961 -- 2.5 The parallel drafting of the SPC and the CEPL (with UPOV 1961 in the background) -- 2.6 The 1960s pause and the arrival of the PCT -- 2.7 The process restarts -- 2.8 The home straight - the Munich Diplomatic Conference of September/October 1973 -- 2.9 Discontent sets in -- 2.10 The 2000 revision of the EPC -- 3 Computer programs -- 3.1 Introduction -- 3.2 The TBoA 3.5.01 (Electricity I) story -- 3.3 What the other Boards were doing -- 3.3.1 Board 3.4.01 (Physics I) -- 3.3.2 Board 3.2.04 (Mechanics IV) -- 3.3.3 The other Boards -- 3.4 The legislative history -- 3.5 The Enlarged Board Opinion - G-3/08 Programs for computers -- 3.5.1 Should the president's referral have been admitted? -- 3.5.2 The divergent decisions -- 3.5.3 The Enlarged Board's reasoning -- 3.5.4 The questions -- 3.5.4.1 Question 1: Can a computer program only be excluded as a computer program as such if it is explicitly claimed as a computer program -- 3.5.4.2 Questions 2, 3 and 4 -- 3.6 Conclusion.
4 Discoveries -- 4.1 Introduction -- 4.2 T-877/92 Removal of carcinogenic hydrocarbons/EXXON -- 4.3 T-869/95 NISSAN MOTOR -- 4.4 T-272/95 Relaxin/HOWARD FLOREY INSTITUTE -- 4.5 T-338/00 Multimeric receptors/SALK INSTITUTE -- 4.6 T-1538/05 ZAGYANSKY -- 4.7 T-1213/05 Breast and ovarian cancer/ UNIVERSITY OF UTAH -- 4.8 T-666/05 Mutation/UNIVERSITY OF UTAH -- 4.9 T-80/05 Method of diagnosis/UNIVERSITY OF UTAH -- 4.10 Comments -- 5 Methods of medical treatment and diagnosis -- 5.1 Introduction -- 5.2 What is therapy? -- 5.3 What has been found to be, or not to be, therapy? -- 5.4 What is surgery? -- 5.5 The aftermath of the Enlarged Board decision on 'surgery' -- 5.6 What would be found to be or not to be surgery? -- 5.7 What is diagnosis? -- 5.8 What would be found to be or not to be diagnosis? -- 5.9 Does the identity of the performer matter? -- 5.10 What happens when the treatment claimed could overlap with an excluded method? -- 5.11 The travaux préparatoires -- 5.12 The contamination approach -- 5.13 Patenting known drug substances -- 5.13.1 Second and further indications -- 5.13.2 The G-5/83 Second medical indication/EISAI Decision -- 5.13.3 G-2/08 Dosage regime/ABBOTT RESPIRATORY decision -- 5.13.4 The Implications of the G-2/08 Dosage regime/ABBOTT RESPIRATORY decision -- 6 Essentially biological processes for the production of plants and animals -- 6.1 Introduction -- 6.2 The law -- 6.3 The key issues -- 6.4 Key decisions -- 6.5 The travaux préparatoires -- 6.6 Possible types of claims and their acceptability in view of the exclusion -- 6.7 Implications -- 6.8 Products of 'essentially biological processes' -- 6.9 The status quo -- 7 Plant and animal varieties -- 7.1 Introduction -- 7.2 Plants: T-49/83 Propagating material/CIBA-GEIGY -- 7.3 Plants: T-320/87 Hybrid plants/LUBRIZOL -- 7.4 Animals: T-19/90 Onco-mouse/HARVARD.
7.5 Plants: T-356/93 Plant cells/PLANT GENETIC SYSTEMS -- 7.6 Plants: G-3/95 Inadmissible referral -- 7.7 Plants: T-1054/96 (I) Transgenic plant/NOVARTIS -- 7.8 Plants: G-1/98 Transgenic plant/NOVARTIS II -- 7.9 Plants: T-149/98 Resistance development/BAYER -- 7.10 Plants: T-1054/96 Anti-pathogenic compositions/NOVARTIS III -- 7.11 Plants: T-475/01 Phosphinothricin resistant gene/BAYER -- 7.12 Plants: T-179/01 Herbicide resistant plants/MONSANTO -- 7.13 Animals: T-315/03 Transgenic animals/HARVARD -- 7.14 Plants: T-788/07 Brassica/PIONEER -- 7.15 Plants: T-1854/07 Oil from seeds/CONSEJO SUPERIOR -- 7.16 Plants: T-775/08 Glyphosate tolerant alfalfa/MONSANTO -- 7.17 General comments -- 7.17.1 How necessary is product protection? -- 7.17.2 The purpose of the exclusion -- 7.17.3 The meaning of 'varieties' -- 7.17.4 The second half-sentence -- 7.17.5 The approach to the exclusion -- 7.18 Conclusion -- 8 Morality and 'ordre public' -- 8.1 Introduction -- 8.2 Animals: T-19/90 Onco-mouse/HARVARD -- 8.3 Animals: T-315/03 Transgenic animals/HARVARD -- 8.4 Animals: T-606/03 Gene trap/ARTEMIS -- 8.5 Plants: T-356/93 Plant cells/PLANT GENETIC SYSTEMS -- 8.6 Plants: T-475/01 Phosphinothricin resistant gene/BAYER -- 8.7 Plants: T-179/01 Herbicide resistant plants/MONSANTO -- 8.8 Controversial medical intervention: T-866/01 Euthanasia compositions/MICHIGAN STATE UNIVERSITY -- 8.9 Human genes and genetic diagnostic tests: T-272/95 Relaxin/HOWARD FLOREY INSTITUTE -- 8.10 Human genes and genetic diagnostic tests: T-1213/05 Breast and ovarian cancer/UNIVERSITY OF UTAH -- 8.11 Human genes and genetic diagnostic tests: T-666/05 Mutation/UNIVERSITY OF UTAH -- 8.12 Human genes and genetic diagnostic tests: T-80/05 Method of diagnosis/UNIVERSITY OF UTAH -- 8.13 Stem cells/embryos: T-1374/04 (I) Stem cells/WARF -- 8.14 Stem cells/embryos: G-2/06 Use of embryos/WARF.
8.15 Stem cells/embryos: T-522/04 Stem cells/CALIFORNIA -- 8.16 General comments -- 8.16.1 The EPO as a 'moral censor' -- 8.16.2 The relevance of the EBD-derived EPC Rules -- 8.16.3 The necessity to consider the Article, rather than (merely) the Rules -- 8.16.4 The meaning of the Article -- 8.16.4.1 The 2000 amendment of the Article -- 8.16.4.2 The concept of 'morality' -- 8.16.4.3 The concept of 'ordre public' -- 8.16.4.4 The concept of 'exploitation' -- 8.16.5 Taking into account how an invention has been developed -- 8.16.6 Special considerations in cases relating to the human body and its parts -- 9 Towards a coherent interpretation of the exclusions -- 9.1 Introduction -- 9.2 Approaches to the exclusions -- 9.3 Art. 52(2) EPC -- 9.4 The implications of the 'anything added plus a requirement for synergy' approach to Art. 52(2) EPC -- 9.5 The Art. 53 EPC exclusions -- 9.6 The implications of the implicit disclaimer approach to Art. 53 EPC -- 10 Conclusion -- Correspondence from EPO files -- References -- Index.
Summary: This book provides the first comprehensive study of what cannot be patented and what should not be patentable in Europe.
Tags from this library: No tags from this library for this title. Log in to add tags.
    Average rating: 0.0 (0 votes)
No physical items for this record

Cover -- Exclusions from Patentability -- Title -- Copyright -- Dedication -- Contents -- Acknowledgements -- Table of cases -- EPO cases -- Enlarged Board of Appeal decisions: -- Technical Board of Appeal decisions: -- Other cases: -- Table of international conventions and regulations -- Table of official documents -- Explanation of document numbering -- Abbreviations -- 1 Introduction -- 1.1 The most basic of the safeguards -- 1.2 The 'New Wealth of Nations' -- 1.3 Natural rights as the foundation for patents? -- 1.4 Distributive justice as the foundation for patents? -- 1.5 Utilitarianism as the foundation for patents? -- 2 The historical development and current scope of the European Patent Convention -- 2.1 Introduction -- 2.2 The international harmonisation of patent law -- 2.3 The early history -- 2.4 Plant variety protection - the negotiations leading to UPOV 1961 -- 2.5 The parallel drafting of the SPC and the CEPL (with UPOV 1961 in the background) -- 2.6 The 1960s pause and the arrival of the PCT -- 2.7 The process restarts -- 2.8 The home straight - the Munich Diplomatic Conference of September/October 1973 -- 2.9 Discontent sets in -- 2.10 The 2000 revision of the EPC -- 3 Computer programs -- 3.1 Introduction -- 3.2 The TBoA 3.5.01 (Electricity I) story -- 3.3 What the other Boards were doing -- 3.3.1 Board 3.4.01 (Physics I) -- 3.3.2 Board 3.2.04 (Mechanics IV) -- 3.3.3 The other Boards -- 3.4 The legislative history -- 3.5 The Enlarged Board Opinion - G-3/08 Programs for computers -- 3.5.1 Should the president's referral have been admitted? -- 3.5.2 The divergent decisions -- 3.5.3 The Enlarged Board's reasoning -- 3.5.4 The questions -- 3.5.4.1 Question 1: Can a computer program only be excluded as a computer program as such if it is explicitly claimed as a computer program -- 3.5.4.2 Questions 2, 3 and 4 -- 3.6 Conclusion.

4 Discoveries -- 4.1 Introduction -- 4.2 T-877/92 Removal of carcinogenic hydrocarbons/EXXON -- 4.3 T-869/95 NISSAN MOTOR -- 4.4 T-272/95 Relaxin/HOWARD FLOREY INSTITUTE -- 4.5 T-338/00 Multimeric receptors/SALK INSTITUTE -- 4.6 T-1538/05 ZAGYANSKY -- 4.7 T-1213/05 Breast and ovarian cancer/ UNIVERSITY OF UTAH -- 4.8 T-666/05 Mutation/UNIVERSITY OF UTAH -- 4.9 T-80/05 Method of diagnosis/UNIVERSITY OF UTAH -- 4.10 Comments -- 5 Methods of medical treatment and diagnosis -- 5.1 Introduction -- 5.2 What is therapy? -- 5.3 What has been found to be, or not to be, therapy? -- 5.4 What is surgery? -- 5.5 The aftermath of the Enlarged Board decision on 'surgery' -- 5.6 What would be found to be or not to be surgery? -- 5.7 What is diagnosis? -- 5.8 What would be found to be or not to be diagnosis? -- 5.9 Does the identity of the performer matter? -- 5.10 What happens when the treatment claimed could overlap with an excluded method? -- 5.11 The travaux préparatoires -- 5.12 The contamination approach -- 5.13 Patenting known drug substances -- 5.13.1 Second and further indications -- 5.13.2 The G-5/83 Second medical indication/EISAI Decision -- 5.13.3 G-2/08 Dosage regime/ABBOTT RESPIRATORY decision -- 5.13.4 The Implications of the G-2/08 Dosage regime/ABBOTT RESPIRATORY decision -- 6 Essentially biological processes for the production of plants and animals -- 6.1 Introduction -- 6.2 The law -- 6.3 The key issues -- 6.4 Key decisions -- 6.5 The travaux préparatoires -- 6.6 Possible types of claims and their acceptability in view of the exclusion -- 6.7 Implications -- 6.8 Products of 'essentially biological processes' -- 6.9 The status quo -- 7 Plant and animal varieties -- 7.1 Introduction -- 7.2 Plants: T-49/83 Propagating material/CIBA-GEIGY -- 7.3 Plants: T-320/87 Hybrid plants/LUBRIZOL -- 7.4 Animals: T-19/90 Onco-mouse/HARVARD.

7.5 Plants: T-356/93 Plant cells/PLANT GENETIC SYSTEMS -- 7.6 Plants: G-3/95 Inadmissible referral -- 7.7 Plants: T-1054/96 (I) Transgenic plant/NOVARTIS -- 7.8 Plants: G-1/98 Transgenic plant/NOVARTIS II -- 7.9 Plants: T-149/98 Resistance development/BAYER -- 7.10 Plants: T-1054/96 Anti-pathogenic compositions/NOVARTIS III -- 7.11 Plants: T-475/01 Phosphinothricin resistant gene/BAYER -- 7.12 Plants: T-179/01 Herbicide resistant plants/MONSANTO -- 7.13 Animals: T-315/03 Transgenic animals/HARVARD -- 7.14 Plants: T-788/07 Brassica/PIONEER -- 7.15 Plants: T-1854/07 Oil from seeds/CONSEJO SUPERIOR -- 7.16 Plants: T-775/08 Glyphosate tolerant alfalfa/MONSANTO -- 7.17 General comments -- 7.17.1 How necessary is product protection? -- 7.17.2 The purpose of the exclusion -- 7.17.3 The meaning of 'varieties' -- 7.17.4 The second half-sentence -- 7.17.5 The approach to the exclusion -- 7.18 Conclusion -- 8 Morality and 'ordre public' -- 8.1 Introduction -- 8.2 Animals: T-19/90 Onco-mouse/HARVARD -- 8.3 Animals: T-315/03 Transgenic animals/HARVARD -- 8.4 Animals: T-606/03 Gene trap/ARTEMIS -- 8.5 Plants: T-356/93 Plant cells/PLANT GENETIC SYSTEMS -- 8.6 Plants: T-475/01 Phosphinothricin resistant gene/BAYER -- 8.7 Plants: T-179/01 Herbicide resistant plants/MONSANTO -- 8.8 Controversial medical intervention: T-866/01 Euthanasia compositions/MICHIGAN STATE UNIVERSITY -- 8.9 Human genes and genetic diagnostic tests: T-272/95 Relaxin/HOWARD FLOREY INSTITUTE -- 8.10 Human genes and genetic diagnostic tests: T-1213/05 Breast and ovarian cancer/UNIVERSITY OF UTAH -- 8.11 Human genes and genetic diagnostic tests: T-666/05 Mutation/UNIVERSITY OF UTAH -- 8.12 Human genes and genetic diagnostic tests: T-80/05 Method of diagnosis/UNIVERSITY OF UTAH -- 8.13 Stem cells/embryos: T-1374/04 (I) Stem cells/WARF -- 8.14 Stem cells/embryos: G-2/06 Use of embryos/WARF.

8.15 Stem cells/embryos: T-522/04 Stem cells/CALIFORNIA -- 8.16 General comments -- 8.16.1 The EPO as a 'moral censor' -- 8.16.2 The relevance of the EBD-derived EPC Rules -- 8.16.3 The necessity to consider the Article, rather than (merely) the Rules -- 8.16.4 The meaning of the Article -- 8.16.4.1 The 2000 amendment of the Article -- 8.16.4.2 The concept of 'morality' -- 8.16.4.3 The concept of 'ordre public' -- 8.16.4.4 The concept of 'exploitation' -- 8.16.5 Taking into account how an invention has been developed -- 8.16.6 Special considerations in cases relating to the human body and its parts -- 9 Towards a coherent interpretation of the exclusions -- 9.1 Introduction -- 9.2 Approaches to the exclusions -- 9.3 Art. 52(2) EPC -- 9.4 The implications of the 'anything added plus a requirement for synergy' approach to Art. 52(2) EPC -- 9.5 The Art. 53 EPC exclusions -- 9.6 The implications of the implicit disclaimer approach to Art. 53 EPC -- 10 Conclusion -- Correspondence from EPO files -- References -- Index.

This book provides the first comprehensive study of what cannot be patented and what should not be patentable in Europe.

Description based on publisher supplied metadata and other sources.

Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2018. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries.

There are no comments on this title.

to post a comment.

Powered by Koha